Genetic Testing

77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey

Staff April 19, 2023

Medication failure leads 45% of respondents with depression and/or anxiety to turn to unhealthy coping mechanisms Respondents may view these behaviors...

Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program

Staff April 12, 2023

New program will increase access to affordable genetic testing while also helping to identify and elevate high-risk patient careSALT LAKE...

Rhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference

Staff April 10, 2023

BOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...

Love for Liam Foundation Announces Formation; Names Board; Will Host Second Annual Golf Outing & Benefit Dinner on May 5, 2023

Staff March 20, 2023

PHILADELPHIA, March 20, 2023 (GLOBE NEWSWIRE) -- The Love for Liam Foundation, a 501(c)(3) nonprofit that seeks to raise awareness...

GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”

Staff March 20, 2023

Genome Sequencing and Interpretation Services Progressing Quickly for 1,000 Newborns Enrolled in Study to Date; On Track to Support up...

Porex Life Sciences Institute Expands Saletto® Filtered Saliva Collection Device to the Genetic Testing Market

Staff March 17, 2023

Revolutionary saliva collection tool standardizes samples through the industry’s first and only filtered collection tip, producing ready-to-use samples that are...

New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare

Staff March 9, 2023

92 percent of doctors in the U.S. say genetics is an important part of a patient’s complete health picture66 percent...

Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics

Staff February 27, 2023

- Rare disease company in preclinical development for congenital hyperinsulinism - - Acquisition is strong strategic fit...

Janssen Receives Positive CHMP Opinion for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) Plus Prednisone or Prednisolone for the Treatment of Adult Patients with BRCA1/2 Gene-Mutated Metastatic Castration Resistant Prostate Cancer

Staff February 24, 2023

If approved, niraparib in combination with abiraterone acetate (AA), will be the first dual action tablet (DAT) available in the European...

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023

Staff February 21, 2023

BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...

Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer

Staff February 16, 2023

Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU1...

Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian Cancer

Staff February 6, 2023

MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader...

Genetic Technologies Announces $5 Million Registered Direct Offering

Staff February 3, 2023

MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global...

GENE to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer

Staff February 3, 2023

MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader...

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

Staff January 23, 2023

- Patients reported clinically meaningful improvements across multiple health-related quality of life measures following 52 weeks of treatment with setmelanotide...

Prenetics Announces Dr. Bayju Thakar as Chief Executive Officer of Prenetics EMEA

Staff January 19, 2023

LONDON and HONG KONG, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and...

Molecular You launches a new preventive solution shown to improve health outcomes over 100 days

Staff January 10, 2023

From a single blood draw, patients receive a comprehensive health assessment and a tailored action plan to help reduce their...

Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors

Staff January 10, 2023

Prenetics has completed the majority stake acquisition of ACT Genomics to spearhead its entry into to the US$80+ billion global...

Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference

Staff January 4, 2023

SALT LAKE CITY, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and...

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

Staff December 28, 2022

LAVAL, Québec, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...